Study: Sirolimus is effective, safe for treatment-resistant autoimmune blood conditions

October 26, 2015

(WASHINGTON, October 26, 2015) - The immunosuppressant sirolimus is an effective and safe steroid-sparing therapy for children and young adults with highly treatment-resistant autoimmune blood conditions, according to a study published online today in Blood, the Journal of the American Society of Hematology (ASH). This treatment is particularly effective in children with autoimmune lymphoproliferative syndrome (ALPS), a chronic genetic disorder characterized by the buildup of white blood cells in the organs.

Patients with ALPS and other autoimmune disorders often have immune systems that destroy their body's own healthy blood cells. The resulting decrease in blood cells causes symptoms such as anemia, uncontrolled bleeding, and infection. Few effective and well-tolerated therapies exist to manage these chronic autoimmune issues. While standard immunosuppressive therapy with corticosteroids may help some patients, others are resistant, intolerant, or cannot successfully maintain healthy blood cell counts when they discontinue medication. Recently, investigators reported that sirolimus successfully resolved these autoimmune conditions in a small group of children with ALPS without causing adverse side effects.

"Patients with ALPS and other chronic autoimmune disorders have few long-term treatment options for managing harmful conditions related to reduced counts of red blood cells, platelets, or white blood cells," said senior study author David Teachey, MD, of the Children's Hospital of Philadelphia. "Corticosteroids are not a permanent solution, as they are often associated with long-term health effects, such as osteoporosis and higher risk of infection."

To improve disease management for patients with ALPS and similar autoimmune disorders, a research team led by Teachey and his colleague Karen Bride, MD, PhD, conducted a multicenter clinical trial evaluating sirolimus in 30 patients ranging from 5 to 19 years old. All study participants were either intolerant or resistant to corticosteroids. Patients received 2 mg/m2 to 2.5 mg/m2 per day of sirolimus in either liquid or tablet form for six months. After six months, those who benefited from the drug were allowed to continue treatment with continued follow-up appointments to monitor toxicities.

Researchers demonstrate that 11 of the 12 children with ALPS achieved normal blood cell counts within one to three months of starting sirolimus. The remaining patient achieved a complete response by 18 months. Additionally, all ALPS patients successfully weaned off steroids and discontinued all other medications within one week to one month after starting sirolimus. Patients remained on treatment for a median of 3.5 years. In addition, investigators observed that patients suffered few adverse side effects after a median follow-up of two years.

While the majority of study participants with similar autoimmune disorders also achieved complete response (8 of 12 patients), it did not occur until three months after start of treatment. Based on these findings, the authors propose use of sirolimus as early therapy for patients with these chronic treatment-resistant autoimmune blood conditions, especially for those with ALPS.

"This study demonstrates that sirolimus is an effective and safe alternative to steroids, providing children with an improved quality of life as they continue treatment into adulthood," said Dr. Teachey. "While further studies are needed, sirolimus should be considered an early therapy option for patients with autoimmune blood disorders requiring ongoing therapy."
Blood, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH), the world's largest professional society concerned with the causes and treatment of blood disorders.

ASH's mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

Blood® is a registered trademark of the American Society of Hematology.

American Society of Hematology

Related Corticosteroids Articles from Brightsurf:

Corticosteroids improve survival in critically ill COVID-19 patients
In a tremendous demonstration of global collaboration, clinician-scientists have pooled data from 121 hospitals in eight countries to find that inexpensive, widely available steroids improve the odds that very sick COVID-19 patients will survive the illness.

Association between treatment with corticosteroids, risk of death among critically ill patients with COVID-19
The results of seven randomized clinical trials with 1,703 critically ill patients with COVID-19 were combined to estimate the association between administration of corticosteroids compared with usual care or placebo and the risk of death after 28 days.

A dual antenatal therapy benefits extreme preterm babies better than either alone or none
Researchers, led by Samuel Gentle, MD, assistant professor of pediatrics in the University of Alabama at Birmingham School of Medicine, report that antenatal treatment with both magnesium sulfate and corticosteroids together yields an increased benefit for children born at 22 to 26 weeks of gestation, compared to no antenatal treatment or with either therapy alone.

Behavioral disorders more common in children exposed to maternal antenatal corticosteroids
Maternal antenatal corticosteroid treatment is standard care when there is a risk for preterm delivery.

New method identifies which asthma patients respond to systemic corticosteroids
Physicians will be able to predict which of their patients with severe asthma are likely to benefit from treatment with systemic corticosteroids -- and which might only suffer their side effects -- with help from a dozen clinical variables researchers have identified using machine learning techniques, say researchers at Carnegie Mellon University and the University of Pittsburgh School of Medicine.

Study reveals a promising alternative to corticosteroids in acute renal failure treatment
In search of an option for the drug known for causing several side effects, scientists describe the anti-inflammatory properties of protein galectin-1 in tests with rats involving ischemia-reperfusion scenarios.

Long-term usage of inhaled corticosteroids may increase risk of bone fractures in patients with COPD
A study published in the February journal CHEST® suggests long-term inhaled corticosteroids (ICS) in patients with COPD may increase risk of bone fractures in both men and women.

Corticosteroids aid healing -- if the timing is right
A corticosteroid can improve the healing of damaged tendons, but it must be given at the right time, according to a new study from Linköping University in Sweden.

Interventions for treating tuberculous pericarditis
Researchers from South Africa and Canada have carried out a Cochrane review update to assess the safety and effectiveness of corticosteroids for treating tuberculous pericarditis.

New medicine shows potential to reduce oral steroid use in severe asthma patients
The results of the trial, published this week in the New England Journal of Medicine, demonstrate that patients treated with a potential new medicine and antibody, called benralizumab, were more than four times likely to reduce their usage of oral corticosteroids than those taking a placebo.

Read More: Corticosteroids News and Corticosteroids Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to